Tralokinumab

Tralokinumab is a monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It works by targeting interleukin 13, a cytokine involved in inflammatory responses.

Tralokinumab 5L6Y

Mechanism of Action

Tralokinumab is a human IgG4 monoclonal antibody that specifically binds to interleukin 13 (IL-13) and inhibits its interaction with the IL-13 receptor. IL-13 is a central mediator in the pathogenesis of allergic inflammation, such as asthma and atopic dermatitis. By blocking IL-13, tralokinumab reduces inflammatory response, which can lead to an improvement in symptoms.

Clinical Trials

Tralokinumab has been studied in several clinical trials for its effectiveness in treating asthma and atopic dermatitis. In a Phase IIb study, tralokinumab showed a significant reduction in the annual asthma exacerbation rate compared to placebo. In a Phase III study for atopic dermatitis, tralokinumab showed significant improvements in the Eczema Area and Severity Index (EASI) score and the Dermatology Life Quality Index (DLQI) score compared to placebo.

Side Effects

Common side effects of tralokinumab include headache, nasopharyngitis, and upper respiratory tract infection. Serious side effects can include hypersensitivity reactions, including anaphylaxis.

Approval

Tralokinumab was approved for use in the European Union in April 2021 for the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.

See Also

• List of monoclonal antibodies
• Clinical trial
• Asthma
• Atopic dermatitis

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia